Candriam SCA’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.8M | Buy |
160,272
+77,680
| +94% | +$5.18M | 0.05% | 282 |
|
|
2026
Q1 | $5.19M | Sell |
82,592
-335,868
| -80% | -$23.4M | 0.03% | 385 |
|
|
2025
Q4 | $27.8M | Buy |
418,460
+174,097
| +71% | +$11.3M | 0.14% | 152 |
|
|
2025
Q3 | $16.4M | Buy |
244,363
+199,908
| +450% | +$15.8M | 0.09% | 204 |
|
|
2025
Q2 | $3.88M | Sell |
44,455
-1,141
| -3% | -$89.4K | 0.02% | 395 |
|
|
2025
Q1 | $3.11M | Sell |
45,596
-5,014
| -10% | -$409K | 0.02% | 417 |
|
|
2024
Q4 | $3.94M | Sell |
50,610
-179,841
| -78% | -$13.3M | 0.02% | 393 |
|
|
2024
Q3 | $15.4M | Buy |
230,451
+114,702
| +99% | +$9.42M | 0.09% | 215 |
|
|
2024
Q2 | $13.1M | Sell |
115,749
-58,167
| -33% | -$7.35M | 0.08% | 224 |
|
|
2024
Q1 | $24.1M | Sell |
173,916
-29,180
| -14% | -$3.67M | 0.15% | 144 |
|
|
2023
Q4 | $25.2M | Sell |
203,096
-116,247
| -36% | -$11.9M | 0.17% | 129 |
|
|
2023
Q3 | $29.8M | Buy |
319,343
+248,729
| +352% | +$28M | 0.21% | 100 |
|
|
2023
Q2 | $9.07M | Buy |
70,614
+12,586
| +22% | +$1.52M | 0.07% | 257 |
|
|
2023
Q1 | $6.21M | Buy |
58,028
+1,462
| +3% | +$164K | 0.04% | 323 |
|
|
2022
Q4 | $6.41M | Sell |
56,566
-69,503
| -55% | -$7.63M | 0.04% | 341 |
|
|
2022
Q3 | $10.2M | Sell |
126,069
-1,630
| -1% | -$138K | 0.07% | 268 |
|
|
2022
Q2 | $9.52M | Buy |
127,699
+31,571
| +33% | +$2.88M | 0.08% | 230 |
|
|
2022
Q1 | $12.3M | Sell |
96,128
-12,848
| -12% | -$1.41M | 0.08% | 226 |
|
|
2021
Q4 | $14.6M | Buy |
108,976
+87,744
| +413% | +$12.6M | 0.09% | 216 |
|
|
2021
Q3 | $2.9M | Sell |
21,232
-924
| -4% | -$117K | 0.02% | 503 |
|
|
2021
Q2 | $2.37M | Sell |
22,156
-36,744
| -62% | -$3.53M | 0.02% | 557 |
|
|
2021
Q1 | $5.23M | Hold |
58,900
| – | – | 0.04% | 366 |
|
|
2020
Q4 | $5.44M | Sell |
58,900
-2,960
| -5% | -$264K | 0.04% | 375 |
|
|
2020
Q3 | $6.38M | Sell |
61,860
-24
| -0% | -$2.51K | 0.06% | 317 |
|
|
2020
Q2 | $6.27M | Buy |
61,884
+34,852
| +129% | +$3.12M | 0.07% | 292 |
|
|
2020
Q1 | $1.45M | Hold |
27,032
| – | – | 0.02% | 594 |
|
|
2019
Q4 | $1.48M | Buy |
27,032
+3,472
| +15% | +$165K | 0.02% | 611 |
|
|
2019
Q3 | $879K | Sell |
23,560
-1,268
| -5% | -$49.3K | 0.01% | 632 |
|
|
2019
Q2 | $926K | Buy |
24,828
+1,776
| +8% | +$55.8K | 0.01% | 664 |
|
|
2019
Q1 | $686K | Buy |
23,052
+3,100
| +16% | +$109K | 0.01% | 681 |
|
|
2018
Q4 | $598K | Buy |
+19,952
| New | +$633K | 0.01% | 670 |
|
Other funds holding DXCM
Candriam SCA's DXCM Position: Q2 2026 in Review
Candriam SCA increased its DexCom (DXCM) stake by 94% in Q2 2026, buying an estimated $5.18M and bringing the position to 160,272 shares worth $10.8M. The position accounts for 0.05% of the portfolio, ranked #282.
Candriam SCA first reported a position in DXCM in Q4 2018 and has held it in 31 quarters since. The position peaked at $29.8M in Q3 2023. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Candriam SCA held 160,272 shares of DexCom worth $10.8M as of Q2 2026.
- Candriam SCA bought 77,680 DexCom shares in Q2 2026, an estimated $5.18M.
- DexCom made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #282 holding.
- Candriam SCA first reported a position in DexCom in Q4 2018 and has held it in 31 quarters since.
- Candriam SCA's DexCom position peaked at $29.8M in Q3 2023.
- 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.